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ABSTRACT
Objectives: To describe recent federal sponsorship of
cost-effectiveness and related health economics research
to provide insight into the functioning of existing research
support systems and assess the roles of federal health
agencies.
Methods: Using the PubMed database, we identiﬁed
cost-effectiveness and related publications citing support
from a US government entity and published during the
period of 1997 through 2001, and audited them for infor-
mation on funding sources, study type, and content focus.
Results: Five Department of Health and Human Services
agencies and centers and the Veterans Administration are
cited as funders in 74% of 520 federally supported health
economics publications we identiﬁed. Three-fourths of
federally supported publications address ﬁve areas of high
disease burden: infections, cancer, HIV/AIDS, cardiovas-
cular disease, and substance abuse. Other high burden
diseases, including mental health, diabetes, and injuries,
receive less attention. Federal support of health econom-
ics studies of health education and care delivery—inter-
vention types underexamined in the ﬁeld—is relatively
strong but most often focuses on substance abuse or men-
tal health services. Each of the top federal funders has a
distinct funding pattern, but there are substantial areas
of overlap within which we could not identify content
domains speciﬁc to one funder or another.
Conclusions: Federal support of health economics
research has paralleled growth in the ﬁeld. Federal
funders support projects consistent with their mission and
focus on high-burden disease areas. However, overlap-
ping funding areas, ambiguity concerning agency interests
within overlapping content areas, and gaps in some dis-
ease and intervention areas suggest that the coordination
of health economics research funding could be improved.
Keywords: cost-effectiveness, federal funding, federal
health agencies, health economics, research priorities.
Introduction
During the past several years, the costs of health
care and particularly of prescription drugs have
once again begun to rise at an increasing rate. At
the same time, consumers’ concern for the quality of
health care has never been greater, reﬂecting both
increased access to information about health care
and a growing awareness of the multiple conse-
quences of medical interventions. The combination
of these factors has spurred purchasers’ interest in
assessing the value of clinical and public health
interventions—in assuring that their health-care
investments return a measurable, positive, and
valuable health outcome.
In an effort to address these concerns, health
services researchers in academia, the pharmaceuti-
cal industry, consulting ﬁrms, and in government
have produced a growing number of cost-effective-
ness, cost–beneﬁt, and related analyses quantifying
the  cost  per  unit  of  outcome  of  health  policies
and clinical interventions. These studies are often
referred to as health economics studies. (The term
health economics is used in two ways in the litera-
ture: to refer to studies of consumer, ﬁrm and mar-
ket behaviors applying economic theory to examine
health care, and to describe the ﬁeld of economic
evaluation examining costs and outcomes of inter-
ventions to inform resource allocation decisions.
We use the term to refer to the latter ﬁeld of study.)
Health economics studies of health-care services are
intended to address speciﬁc questions regarding the
value of newly developed and existing interventions
and to provide summary information linking health
outcomes and economic impact for use in clinical
and policy decisions. Between 1979 and 1984, an
average of 113 cost-effectiveness analyses (CEAs)
and cost–beneﬁt analyses (CBA) were published
each year [1]. A decade later, these studies were
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being published about three times that rate [2], with
growth occurring across medical modalities and in
the United States, as well as internationally.
Although its role in using and promoting health
economic considerations in health-care decision
making has been fraught with controversy [3], the
federal government has been a signiﬁcant funder
of health economics studies for nearly two decades.
Although health economics is often listed among
agency research interests, most federal efforts in
this area have been opportunistic. Funders, by and
large, have offered only general guidance as to
their interests and priorities for applied health eco-
nomics research or methods. With few exceptions,
health economics studies have been supported
within research portfolios addressing broad sub-
stantive areas. This has led to some confusion
among health-care researchers about agency inter-
ests and about where to seek funding for a given
study. It is also unclear whether federal funders
are addressing important topics and supporting a
coherent and cohesive base of health economics
information.
This report reviews the recent federal sponsor-
ship of health economics research focusing on
health-care services to provide insight into the func-
tioning of the research support systems that are cur-
rently in place. We examine whether the output of
federally sponsored studies is keeping pace with the
increased level of interest in health economics, the
substantive focus of this research, and the speciﬁc
roles of the federal agencies.
Conditions
We examine the health conditions that are the
focus of federally supported health economics
research, considering the level and distribution of
publications addressing various conditions. Ide-
ally, health economics studies should address areas
in which the research could improve delivery of
services, resulting in greater health outcomes for
health-care dollars invested. Opportunities for this
improved efﬁciency depend on many factors, some
of which can be difﬁcult to identify: the potential
of new interventions, implementation considera-
tions, the current efﬁciency of interventions, dis-
ease burden (morbidity, mortality, and cost), and
other factors [4]. Efforts to guide the allocation
of resources devoted to medical research have fre-
quently highlighted measures of health and eco-
nomic disease burden [5–8]. The allocation of
health economics research dollars among disease
areas has received less attention. Chapman et al.
[9], in their review of cost-utility analyses (CUAs),
compare the emphasis given to different disease
types grouped by the International Classiﬁcation of
Diseases, Ninth Revision category. They note that
certain areas, such as circulatory system, infectious
and parasitic diseases, and neoplasms have been
well studied in this literature, while others, includ-
ing congenital anomalies, injuries, and pregnancy,
childbirth and puerperium, have been the subject
of fewer studies.
Interventions
An important concern in the funding of health eco-
nomics research is the type of intervention being
examined. Financial incentives support the evalua-
tion—including the health economics evaluation—
of some types of interventions disproportionately.
In the area of pharmaceuticals, for example, rising
costs have motivated closer attention to the cost-
effectiveness of drugs internationally, and reim-
bursement systems in several countries have
developed formal processes for the review of the
cost-effectiveness of pharmaceuticals [10,11].
Factors other than regulation and reimburse-
ment incentives may also drive health economics
research. More tangible interventions, such as drugs
and tests, are often easier to describe and quantify
than health education, medical procedures, or care
delivery models and may therefore be studied more
often. Outcomes data are more readily available for
drugs than for most other types of intervention, for
example, because of the trials required for drug
approval [12]. In some areas, government and pri-
vate sector entities have explicitly called for greater
use of cost-effectiveness and related studies to assist
in documenting the value of services. This is the case
for prevention, where the Partnership for Preven-
tion and others argue that indications of the relative
value of services are important to help clinicians pri-
oritize among many interventions that offer beneﬁt
[13].
Role of  Agencies
Federal government funding of health economics
research derives from a variety of agencies and cent-
ers within agencies with interests in diverse clinical
and health policy questions. Although there is no
central coordination of these efforts, health eco-
nomics research is at times coordinated informally
and sometimes formally. Projects range from grants
funded under joint requests for proposals, to
interagency  participation  in  workgroups  such  as
the Panel on Cost-Effectiveness in Health and Med-
icine, which published standards for cost-effective-
ness analyses, to joint sponsorship of independent
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reports such as that currently being produced by the
Institute of Medicine Committee to Evaluate Meas-
ures of Health Beneﬁts for Environmental, Health,
and Safety Regulation on beneﬁt measures for use in
cost-effectiveness analyses.
We examine the types and distribution of
health economics research funded by federal cent-
ers and agencies. We investigate the extent to
which agency roles complement or reinforce each
other, look for areas of redundancy, and consider
areas that may require strengthening. In addition,
we look at how investigators rely on single versus
multiple sources of funding within the Dep-
artment of Health and Human Services (DHHS)
and from other government and nongovernment
sources.
Methods
We used published studies as an indicator of suc-
cessful federal research output in cost-effectiveness
and related research. Although not the only mech-
anism for dissemination of research results, publi-
cation in the health and medical literature is the
primary means recognized by health economics
funders and researchers for contributing to the
knowledge base.
We identiﬁed health economics articles pub-
lished from  1997  through  2001,  for  which  the
US government provided some or all funding. We
deﬁned our studies of interest to include the gener-
ally accepted forms of health economics analysis—
cost-effectiveness, cost–utility, cost-minimization,
and beneﬁt-cost analysis—examining both the costs
and health outcomes of a health intervention or
program. We also included other speciﬁc studies
clearly intended to inform a health economics
study. Thus, some economic studies, such as cost-
of-illness or burden-of-illness studies, were not rou-
tinely included. These, methods and other studies
citing an explicit, direct link to health economics
research, however, were included—for example
studies developing or testing general or disease-spe-
ciﬁc outcomes measures for use with cost-effective-
ness analyses.
We limited the publications in our analysis to
research reports, reviews, and tutorials, excluding
editorials, letters, and comments. We excluded arti-
Figure 1 Organizational location of  federal departments and agencies funding economics research in health care.
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cles that did not address a health topic, for example
analyses concerning animals or evaluating basic
science protocols.
To locate health economics studies, we con-
ducted a search of the National Library of Medi-
cine’s (NLM) PubMed database, a comprehensive
and readily accessible database of health and
medical literature. We used the following keywords
and iterations of them: cost-effective, cost-minimi-
zation, cost–utility, cost–beneﬁt, cost–consequence,
pharmacoeconomic, costs and life-year, and costs
and QALY, and identiﬁed articles indicating federal
sponsorship using PubMed’s standardized search
tags. In most cases PubMed captured agency
sponsorship; when it did not, we retrieved the arti-
cle to identify agencies cited. We supplemented the
PubMed search with an inquiry to DHHS agencies
and centers. Contacts in these centers identiﬁed
published intramural research projects with eco-
nomic analysis components. We obtained addi-
tional citations from the Veteran’s Administration’s
Health Economics Resource Center Web site
(http://www.herc.research.med.va.gov/pubs.htm).
We obtained abstracts for all publications
meeting the search criteria. After one researcher
screened out articles not related to clinical econo-
mics, three researchers audited the remaining
abstracts independently, using a standardized for-
mat to capture funding sources, intervention type,
and condition being investigated. When abstracts
did not provide sufﬁcient information, we obtained
the full article for review. Following abstraction,
the auditors met to reconcile results. We identiﬁed
12 main categories of condition that capture pri-
mary causes of US morbidity and mortality: can-
cers, cardiovascular disease and stroke, congenital
abnormalities and genetic disorders, communica-
tion disorders, diabetes, HIV/AIDS, other infectious
or parasitic diseases, injury, mental health, neu-
rological disorders, substance abuse, and other
illnesses. Interventions were grouped into 10
categories: pharmaceuticals; medical devices;
screening; diagnostic; surgical procedures; medical
procedures; care delivery (i.e., studies addressing
modes or strategies for delivering interventions);
immunization; health education, including beh-
avior change and counseling interventions, and
environmental health interventions [9]. We further
classiﬁed interventions as preventive, diagnostic, or
treatment and distinguished among types of pre-
ventive measures.
In assessing the distribution of categories of
health economics publications, variables were ana-
lyzed by using chi-square tests.
Results
Federal Funders: Who Supports Health 
Economics Research?
We screened 1320 articles identiﬁed by our search
string and an additional 105 publications submitted
by the DHHS agencies. We identiﬁed a total of 544
health economics and related articles published
from 1997 through 2001, for which a Federal gov-
ernment agency provided full or partial support.
This total included 520 articles that focused on a
health economics topic and an additional 24 arti-
cles, mostly clinical reviews that included a health
economics component but were not primarily
health economics articles. In the analyses that fol-
low, we refer to the subset of 520 economic studies
unless otherwise noted.
Not surprisingly, DHHS agencies were cited as
funders in 435 (84%) of the federally funded pub-
lications (Table 1). Federal funders outside DHHS
included organizations such as the Department of
Veterans Affairs, the National Science Foundation,
the US Agency for International Development, and
the Department of Education (Fig. 1). A full list of
federal funders is provided in Appendix A.
A majority of articles citing federal support
(60%) credited a single agency or center. In many
cases, however, authors brought together multiple
funding sources either within or outside of the fed-
eral government (Table 1). Nongovernment funders
of these studies included, for example, pharmaceu-
tical companies, foundations, other national gov-
ernments (e.g., United Kingdom), and academic
institutions.
A total of 28 different entities (i.e., separate
grant-making units) funded the DHHS economic
studies. Most were agencies, but, particularly in
the case of the National Institutes of Health (NIH),
some were institutes or centers within a large
agency. The top ﬁve DHHS funding entities were
cited in more than half of studies in which a fed-
eral funding  source  was  identiﬁed.  These  were
the Agency for Healthcare Research and Quality
(AHRQ) and the Centers for Disease Control and
Prevention (CDC), each cited in 15% of all feder-
ally supported studies; the National Institute for
Mental Health (NIMH) and National Cancer Insti-
tute (NCI), each cited in 11%; and the National
Institute on Drug Abuse (NIDA), cited in 10% of
studies. Other frequent funders within the DHHS
included the National Heart Lung and Blood Insti-
tute (NHLBI) and National Institute on Aging
(NIA), each of which was cited in more than 5%
of studies. The largest non-DHHS federal funder of
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health economics studies is the Department of
Veterans Affairs (VA), which was identiﬁed as a
funder in 68 (13%) of the abstracts we reviewed.
No other funder was cited in more than 5% of the
studies.
As in the health economics literature overall, we
found the annual number of publications per year
citing federal funding to be increasing. From 1997
to 2001, the number of publications citing federal
funding increased from 87 to 117 in a steady
upward trend (P = 0.009). This trend is visible in
articles citing DHHS funding, although it does not
reach statistical signiﬁcance (P = 0.07).
Disease Area
Table 2 details the conditions studied in the 520 fed-
erally sponsored analyses. Two-thirds of these stud-
ies address one or more of the most frequently
addressed ﬁve conditions: infectious diseases (other
than HIV, which was tracked separately because of
its size), cancer, HIV/AIDS, substance abuse, and
cardiovascular disease, including stroke.
The ﬁve areas emphasized in federal health eco-
nomics studies rank among important disease areas
as measured by indicators of years of potential life
lost [7,14], actual causes of death [15], and/or eco-
nomic burden [5]. All are focus areas used to deﬁne
the leading health indicators in Healthy People
2010 (USDHHS 2000) [16]. Other areas ranking
high on the basis of these indicators, however,
receive much less attention. These include mental
health, which is addressed in 28 of the 458 articles
that consider at least one disease area; injuries,
which are the subject of only 13 publications; arthri-
tis, addressed in 6 publications; chronic obstructive
pulmonary disease (COPD) and asthma, addressed
in a total of 5, and dementia, addressed in 2.
Infectious  diseases. Ninety-two federally sup-
ported health economics articles–-20% of studies
listing a condition––address infectious diseases, one
Table 1 Health economics publications supported by federal funding entities 1997–2001
Funding entity
(budget $ in millions)*
No. (%) of
federally
supported
publications
Sole funder
cited no. (%)
of  entity’s
publications 
No. of  agency publications
citing multiple sources of  support
Other government
funder cited†
Other
nongovernment
funder only
DHHS
AHRQ (213) 77 (15) 35 (45) 34 8
CDC (3199) 77 (15) 47 (61) 24 6
NCI (3315) 55 (11) 32 (58) 16 7
NIMH (972) 55 (11) 29 (53) 24 2
NIDA (695) 51 (10) 27 (53) 21 3
NHLBI (2027) 35 (7) 23 (66) 6 6
NIA (686) 29 (6) 14 (48) 11 4
NIAID (1777) 23 (4) 3 (13) 18 2
NIDDK (1167) 23 (4) 9 (39) 11 3
NCRR (676) 20 (4) 6 (30) 12 2
NLM (214) 13 (3) 4 (31) 8 1
NIAMS (349) 12 (2) 5 (42) 4 3
NIAAA (292) 11 (2) 2 (18) 8 1
HRSA (4746) 11 (2) 5 (45) 6 0
NICHD (857) 9 (2) 1 (11) 6 2
NEI (450) 9 (2) 3 (33) 5 1
NINDS (1028) 5 (1) 2 (40) 2 1
Other NIH 16 (3) 4 (25) 5 7
Other DHHS 9 (2) 3 (33) 6 0
Total DHHS Publications
(382.6 billion)
435 (84)§ 254 (58) 122 59
Non-DHHS VA (352)‡
NSF (3050)
68 (13)
14 (3)
38 (56)
1 (7)
18
5
12
8
USAID (1224) 10 (2) 7 (70) 1 2
DOE 10 (2) 6 (60) 3 1
Army 8 (2) 3 (38) 5 0
Other government
 (non-DHHS)
18 (3) 3 (17) 11 4
Total federally
supported publications
520§ 312
*Budget information reﬂects Programming and Financing Expenses from the Budget of  the United States Government: Appendix Fiscal Year 2002 (http://www.gpoac-
cess.gov/usbudget/fy02/browse.html).
†Includes articles citing support from both other US government and nongovernment sources, as well as those citing only other US government support.
‡VA budget is total medical research expenses for the Department of  Veterans Affairs (see source in note 1).
§The total does not equal the sum of  agency sponsored publications above because of  multiple sponsorship of  some publications.
See Appendix A for deﬁnitions of  entity abbreviations.
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of the primary root causes of death in the United
States  as  well  as  a  major  contributor  to  morbid-
ity [15]. Certain infectious-disease deaths have
increased because of their impact on HIV-infected
populations; 16 studies focus on these conditions
among persons with HIV, most examining treat-
ments for opportunistic infections. Others address
screening, e.g., for tuberculosis or human papillo-
mavirus, or prevention of sexually transmitted dis-
eases in HIV-infected populations.
Non-HIV-related infections represent the fourth
leading actual cause of death nationally [15]. Sev-
enty-six articles target these diseases. Thirty-one
examined an immunization strategy for prevention
of cholera, inﬂuenza, adenovirus, helicobacter
pylori, or other infection, or a system (e.g., a
reminder system) for increasing immunization
compliance generally. An additional 22 of the infec-
tious-disease studies addressed a pharmacological
treatment strategy, while 10 others evaluated
screening strategies, mostly for sexually transmitted
diseases. The remaining studies address a wide
range of interventions, from blood banking, surveil-
lance, and sanitation systems, to the prevention of
infections associated with surgeries and implanted
medical devices.
Cancer. Cancer, the second leading cause of deaths
in the United States [5,17] and the second leading
cause of years of life lost [7], is the focus of 69 fed-
erally supported health economics studies. Nine of
these deal with methods, e.g., how to determine
costs of cancer care or how to assign values to can-
cer health outcomes for economic analysis. Among
the 60 studies that assess an intervention, 37
address a prevention strategy (usually screening), 14
address a treatment strategy, and 7 a diagnostic
strategy.
About a third (19) of the health economics stud-
ies of cancers concern the prevention, diagnosis, or
treatment of breast cancer, the highest incident can-
cer for women and their second leading cause of
death [18]. For prostate cancer, which has a similar
importance among men, however, only two studies
have been supported. A number of articles address
colorectal cancer (12) and hematological malignan-
cies (7), both leading causes of cancer deaths, and
cervical cancer (6), a cancer that is highly prevent-
able and which, although imposing a lesser burden
domestically, remains an important cause of cancer
deaths in developing countries [19]. Only a single
study addresses lung cancer, the leading cause of
cancer deaths for men and women.
HIV/AIDS. Sixty-four health economics studies
address HIV infection, which, although not a lead-
ing cause of death in the United States, is responsi-
ble for a disproportionate number of lost life-years
[7]. A majority of the HIV articles address preven-
tion, with about half examining primary prevention
measures to prevent HIV transmission to uninfected
populations. These include drug, screening, and
health education interventions targeting many
groups, including gay adolescents, infants of HIV-
infected mothers, transfusion recipients, prison
populations, mentally ill populations, partners of
Table 2 Conditions addressed in federally supported health economics research
Condition
Total AHRQ CDC NIMH NCI NIDA VA Other
No. %* No. %* No. %* No. %* No. %* No. %* No. %* No. %*
Infections (other than HIV/AIDS) 92 20 19 31 36 49 3 6 3 6 4 8 7 13 39 20
Cancer 69 15 8 13 3 4 0 0 43 88 0 0 5 9 23 12
HIV/AIDS 64 14 10 16 22 30 28 58 1 2 19 40 3 5 20 10
Cardiovascular disease and stroke
Substance abuse
56
56
12
12
17
2
27
3
1
3
1
4
0
3
0
6
1
3
2
6
0
34
0
71
11
10
20
18
35
12
18
6
Mental health 28 6 3 5 0 0 21 44 0 0 1 2 5 9 2 1
Multiple conditions addressed in article 28 6 4 6 4 5 0 0 2 4 1 2 3 5 19 10
Congenital Abnormalities 14 3 5 8 1 1 0 0 3 6 0 0 2 4 8 4
Diabetes 13 3 0 0 1 1 0 0 0 0 0 0 5 9 8 4
Injury 13 3 0 0 8 11 0 0 0 0 0 0 2 4 4 2
Pregnancy 10 2 1 2 3 4 1 2 0 0 1 2 0 0 7 4
Gastrointestinal conditions 9 2 0 0 2 3 0 0 0 0 0 0 4 7 4 2
Osteoporosis 7 2 0 0 0 0 0 0 0 0 0 0 0 0 7 4
Arthritis 6 1 0 0 2 3 0 0 0 0 0 0 0 0 4 2
Other conditions (fewer than 5 studies
of  each)
52 11 6 10 2 3 1 2 0 0 0 0 5 9 39 20
Total articles listing at least one
condition funded by each agency†
458 62 73 48 49 48 55 192
*Proportion of  articles, among those listing any condition, that list this condition. Percentages may sum to greater than 100%, because articles may list 1, 2, or 3 con-
ditions. (Articles listing more than 3 conditions are categorized as listing “multiple conditions,” and the conditions are not identiﬁed separately.).
†An additional 62 Federally supported studies did not address a condition.
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infected individuals, and health workers. Seventeen
studies address pharmacologic treatment or
prophylaxis for HIV-infected populations, including
both treatment of opportunistic infections and
antiretroviral therapy, and several additional studies
address screening for opportunistic infections.
Cardiovascular disease. Fifty-six articles focus on
cardiovascular disease, the leading cause of death
and of lost life-years in the United States [7,17],
including coronary artery disease (15 articles),
arrhythmias (13), risk factor modiﬁcation (interven-
tions for hypertension and cholesterol lowering) (8),
vascular conditions (8), and stroke (6). Six addi-
tional articles address a variety of less common
conditions, such as cardiac and vascular infections,
congenital abnormalities, or cardiomyopathy.
Excluding several methods studies, 33 of the car-
diovascular disease publications deal with diag-
nostic or treatment interventions, while 17 focus on
prevention. The studies address a wide range of
interventions, including drug treatments, medical
and diagnostic devices, medical procedures, and
surgical procedures. Among these articles, however,
only ﬁve evaluate a health-education, diet, or nutri-
tion intervention.
Substance  abuse. Fifty-six publications address
substance abuse, the set of conditions imposing
the largest disease-related economic burden in the
United States and underlying signiﬁcant mortality
from cirrhosis, motor vehicle accidents, injuries,
and HIV infection [5,15]. Three-quarters of the sub-
stance abuse publications (42), address substance
abuse involving drugs, including some that involve
both alcohol and drugs, and a majority of these
address some facet of substance abuse treatment.
We identiﬁed 11 that speciﬁcally address the phar-
macologic treatment of opiate addiction. An addi-
tional 13 focus on another treatment approach
(e.g.,  self-help  groups,  therapeutic  communities,
or couples counseling) or on a program’s setting or
delivery mode (e.g., hospital inpatient treatment,
telephone management, supportive housing, or
community outpatient treatment). The remaining
substance abuse studies address tobacco use (mostly
assessing smoking cessation or smoking prevention
programs) and alcohol abuse.
Intervention Modality
The  federally  supported  health  economic  studies
are concentrated in several intervention areas. After
excluding articles that did not address or specify an
intervention (mostly methods articles), 424 studies
of interventions remained (Table 3). The top ﬁve
types of intervention are included in 317 (75%) of
these studies. Economic analyses of pharmaceuti-
cals are the most numerous, accounting for 120
(28%) of the articles that consider speciﬁc interven-
tions. Health education was the next most frequent
intervention type, examined in 77 (18%) of the arti-
cles. Screening studies, mostly in the areas of cancer,
HIV, or infectious-disease screening, accounted for
75 (18%). Fifty-one (12%) addressed care delivery,
and 48 (11%) addressed diagnostic tests.
Devices, medical procedures, and surgical proce-
dures, relatively broad areas of intervention in
health care, received somewhat less emphasis than
the other broad intervention types. Thirty-two (8%)
of studies evaluated a device, while 25 (6%) each
dealt with medical procedures and surgical proce-
Table 3 Number and proportion of  agency supported publications addressing intervention type
Type of  intervention
Total* AHRQ CDC NIMH NCI NIDA VA Other
No. %† No. %† No. %† No. %† No. %† No. %† No. %† No. %†
Pharmaceuticals 120 28 23 41 14 19 14 33 7 16 14 34 17 33 44 29
Health education 77 18 5 9 11 15 23 53 7 16 16 39 4 8 16 11
Screening 75 18 11 20 12 17 7 16 21 48 6 15 11 22 16 11
Care delivery 51 12 4 7 6 8 7 16 3 7 8 20 4 8 20 13
Diagnostics 48 11 6 11 4 6 1 2 6 14 0 0 10 20 22 14
Devices 32 8 11 20 1 1 1 2 2 5 1 2 4 8 17 11
Immunization 32 8 1 2 19 26 0 0 0 0 0 0 2 4 12 8
Other interventions 28 7 1 2 12 17 3 7 0 0 3 7 3 6 10 7
Multiple intervention types 27 6 4 7 8 11 1 2 1 2 2 5 2 4 11 7
Surgical procedures 25 6 2 4 1 1 0 0 2 5 0 0 3 6 17 11
Medical procedures 25 6 4 7 0 0 1 2 2 5 2 5 5 10 12 8
Environmental 5 1 0 0 0 0 0 0 0 0 0 0 0 0 5 3
Total (articles addressing/specifying
at least one intervention)
424 — 56 — 72 — 43 — 44 — 41 — 51 — 152 —
*Numbers of  articles will not sum to this total across agencies because of  multiple funding sources for some publications.
†Proportion of  articles, among those listing any intervention, that list this intervention. Percentages sum to greater than 100%, because many articles examine more than
one type of  intervention.
See Appendix A for deﬁnitions of  abbreviations.
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dures. Immunizations were assessed in 32 studies
(8%).
Although health education interventions were
included in a substantial portion of studies, these
articles focus on interventions for relatively few
conditions. Forty-eight of the 77 health education
studies deal with education and behavioral int-
erventions in substance abuse, mental health, and
HIV/AIDS prevention. The emphasis on health edu-
cation in these ﬁelds obscures a lower level of atten-
tion to this type of intervention in addressing other
conditions. Only 29 articles address health educa-
tion in cancer, cardiovascular disease, back pain,
arthritis, diabetes, and other areas.
The articles on health-care delivery display a sim-
ilar pattern. Of the total 51 articles, 22 address the
delivery of substance abuse or mental-health serv-
ices, while an additional 9 address delivery of infec-
tious-disease services, including immunizations.
Health economics studies in these rather specialized
areas thus comprise a majority of all studies on care
delivery. Only 11 studies address care delivery for
speciﬁc chronic diseases: cancer, cardiovascular
care,  diabetes,  asthma,  and  delirium.  Most  of
the remaining studies address delivery strategies for
other geriatric care (largely funded by NIA) or
maternal and child health.
Methods Studies
Of the 520 health economics studies we examined,
108 (21%) were methods studies. These address a
range of topics in health economics, including sta-
tistical issues such as sample size and power calcu-
lations, handling uncertainty, methods for synthesis
of health economics studies, modeling methods,
health outcome valuation, and costing methods.
AHRQ was the largest supporter of methods
studies, providing full or partial support for 25
studies (23%). VA was the next largest contributor,
with 19 studies (18%). Following these, several
NIH funders—NIMH, NCI, NIA, NHLBI, and
NIDA—each provided support for about 10% of
the studies.
Institutions: Funding Focus for Top Funding Entities
AHRQ. AHRQ supports and conducts research on
health-care outcomes; quality; and cost, use, and
access to inform and assist health-care decision
makers, i.e., patients and clinicians, health system
leaders, purchasers of health services, and policy-
makers. Within AHRQ, the Research Initiative in
Clinical Economics coordinates efforts in cost-
effectiveness and related research.
AHRQ is one of the two largest funders of health
economics research within DHHS. As noted above,
it is also the largest DHHS funder of methods
research in CEAs, providing partial or full support
for 25 (23%) of the 108 methods publications
we identiﬁed. These studies have included work in
assessing health outcomes, effectiveness, and cost
for health economics studies, model development,
and reviews of health economics studies.
The largest condition area in AHRQ’s health eco-
nomics portfolio is infections, followed closely by
cardiovascular disease. About half of the infection
studies concern infections in HIV-infected popula-
tions. Others deal with sexually transmitted dis-
eases and hospital-acquired infections. The studies
in the area of cardiovascular disease address both
preventive interventions, such as educational and
pharmacologic approaches to lowering serum cho-
lesterol, and therapeutic interventions including
drugs, devices, and some surgical procedures.
AHRQ also funds a number of health economics
studies in the areas of cancer, HIV, and congenital
abnormalities. In comparison with the other top
producers of CEAs, AHRQ’s portfolio is broadly
distributed (Table 2). No single area is a dominant
focus, and multiple studies have been supported in
several areas. Several AHRQ-supported publica-
tions compare multiple interventions within a
deﬁned condition area, and a few additional studies
cross conditions and/or intervention types, such as
one study examining care for high-risk infants and
two that address a range of clinical preventive
services.
This breadth of interest is also apparent in the
types of intervention examined in the health eco-
nomics studies that AHRQ has supported: the
agency has supported at least one study of every
type of health-care intervention we examined, with
the exception of environmental-health interven-
tions. A substantial portion of AHRQ’s studies
assess a pharmaceutical intervention, although
many of these studies include other alternatives.
AHRQ also plays a primary role in supporting
studies of medical devices. Surprisingly, given the
agency’s commitment to research on the spectrum
of health-care practices, technologies, processes,
and systems [20], AHRQ has not funded many
health economics studies of medical or surgical pro-
cedures, health education, or care delivery—ﬁve or
fewer studies in each of these areas over the 5-year
period we examined.
CDC. The CDC, the DHHS agency dedicated to
preventing and controlling disease, injury and disa-
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bility, is another prominent supporter of health
economics in the federal government. This agency
funded the same number of health economics
studies as AHRQ over the period we examined. Not
surprisingly, the CDC health economics research
has addressed primarily infectious disease, HIV/
AIDS, and, to a lesser extent, injuries. Studies
addressing one or more of these topics account for
about four-ﬁfths of the CDC’s economic analysis.
The remainder of CDC-supported studies address
topics including environmental tobacco smoke,
elevated lead levels, and multiple preventive
interventions.
The CDC is the leading sponsor of health
economics studies of preventive interventions, fund-
ing more than twice as many as any other federal
funder. The CDC was a supporter of 60 of the total
221 articles on preventive interventions and more
than half of the studies of immunizations. Although
the  CDC  was  cited  as  a  funder  in  17  articles
on community preventive services—more than any
other federal funder—the agency was cited in many
more studies of clinical preventive services. These
included screening and chemoprophylaxis interven-
tions, in addition to immunization services.
VA. The health services research program at the VA
addresses access, outcomes, and cost issues relevant
to the VA and includes a Health Economics
Resource Center that assists VA researchers in
conducting cost-effectiveness and related studies.
VA-supported health economics research has emp-
hasized methodological research and studies in car-
diovascular disease and substance abuse. The most
frequent intervention types examined are pharma-
ceuticals, screening, and diagnostics, which repre-
sent a relatively large part of the VA portfolio. Less
emphasis is placed on studies of health education
interventions, care delivery, or immunizations.
NIMH.  The NIMH is charged with diminishing
the burden of mental illness in the United States
and, in addition, is one of four lead institutes sup-
porting AIDS research at the NIH. Of the 55 health
economics studies that the NIMH published during
the past 5 years, 21 address mental health, 28
address HIV/AIDS, and the remainder were meth-
ods studies. The NIMH was cited as the sole funder
for about three-fourths of the mental health studies,
in contrast with the HIV/AIDS studies, most of
which were funded jointly with other agencies.
The NIMH-supported mental-health economics
studies generally address treatment interventions,
most frequently aimed at depression, schizophrenia,
or other severe mental illness. Several studies target
persons with dual diagnosis or homeless popula-
tions. The HIV/AIDS studies to which NIMH has
contributed are mostly aimed at the prevention of
HIV transmission.
NCI. The NCI funds the majority (62%) of feder-
ally supported health economics studies addressing
cancer, including studies of cancer prevention, diag-
nosis, and treatment. Most of the prevention studies
assess screening interventions, particularly for
breast, colorectal, or cervical cancer. Several addi-
tional studies address smoking cessation inter-
ventions. The NCI is also an important source of
support for methodological work.
NIDA. About two-thirds of the health economics
studies that NIDA have supported (34 out of 51
studies) address substance abuse interventions
directly. These include alcohol and drug abuse pre-
vention and treatment. Nineteen studies address
HIV/AIDS interventions, most of these prevention
related. Some of the HIV studies are relevant for
general populations, e.g., analyses of the prevention
of cytomegalovirus or other opportunistic infec-
tions among HIV-infected individuals, or of meas-
ures to prevent vertical transmission of HIV. Others
target substance-abusing populations, examining
the cost-effectiveness of needle exchange programs
or HIV treatment strategies for drug users. The
remaining studies supported by NIDA address
health economics methods.
Areas of  Overlap
Although each of the top federal funders of health
economics studies has a distinct pattern of funding,
two or more funders devoted a substantial propor-
tion of their total effort to several of the disease
areas we examined, raising questions about dupli-
cation of effort. In infectious disease, HIV/AIDS,
cardiovascular  disease,  and  substance  abuse,  at
least two agencies were cited as funders in 10 or
more publications; in each case these publications
accounted for more than 15% of the health eco-
nomics publications in which the agency was cited
as a funder. We examined the publications in each
of these areas more closely to gain insight into
whether the overlap amounted to a duplication of
effort, or whether the agencies are serving comple-
mentary roles within disease areas.
For health economics studies of HIV/AIDS, there
is a difference in the distribution of intervention
type among articles citing the top funders of HIV/
AIDS publications, AHRQ, NIDA, NIMH, NIAID
(subsumed under “Other” in Table 2) and CDC
(P < 0.001). The clearest distinction is between
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AHRQ, which focuses its support predominantly
on secondary and tertiary prevention, i.e., mostly
treatment of opportunistic infection, and NIDA and
NIMH, which place a greater emphasis on primary
prevention. In the other disease areas, however, we
could not identify differences in patterns of support.
For example, although in cardiovascular disease, we
found that NHLBI supports studies related to the
heart, while AHRQ and VA studies address inter-
ventions affecting diseases of the peripheral vascu-
lature, as well as of the heart, the difference was not
statistically signiﬁcant. Similarly, although VA sub-
stance abuse studies focus heavily on diagnosis and
treatment, NIDA, although  supporting  a  broader
range  of  studies,  still conducts more studies in the
area of substance abuse  diagnosis  and  treatment
than  does  VA.  In infectious disease, the only dif-
ference we could identify was due to AHRQ’s
focus on opportunistic infections for HIV-infected
individuals.
Discussion
Recent growth in the ﬁeld of health economics is
reﬂected in an increasing number of health econom-
ics publications supported by the federal govern-
ment. Dozens of agencies and institutes throughout
the federal government contribute to health eco-
nomics research. The most frequently cited support-
ers of this research, however, are several agencies
and institutes within the DHHS and the VA.
A central concern in reviewing federally funded
health economics research is the appropriateness of
the level of emphasis that funders place on various
disease areas. We found that recent federally
funded health economics research has focused on
infections, cancer, HIV/AIDS, cardiovascular dis-
ease, and substance abuse. These are all important
topics based on at least one measure of disease bur-
den or health research priority. Cancer, heart dis-
ease, and substance abuse are three of the leading
causes of death, years of potential life lost, and
economic burden on the US population. Infectious
diseases and HIV/AIDS are important but lower-
ranking priorities based on measures of disease bur-
den. The notable attention devoted to these two
areas may be justiﬁed based on considerations such
as the relative recentness of HIV/AIDS and meas-
ures to combat it, or in the case of infectious
diseases,  factors  such  as  an  implicit  requirement
to provide evidence of cost-effectiveness for pop-
ulation-based preventive services or the strong
traditional role of government in combating com-
municable diseases.
What  is  more  questionable  is  the  relative  lack
of attention given to health economics analyses in
other important disease areas. In 5 years, federal
entities were cited as funders of only 13 studies each
in the areas of diabetes and injuries. In mental
health, an area ranking high in terms of disease and
economic burden, the number of publications is con-
siderably higher—28—but still much lower than the
numbers of studies focusing on other high-burden
disease areas. Similarly, arthritis, COPD, asthma,
and dementia all rank high in terms of disease bur-
den but are the subject of few health economics stud-
ies. It is possible that there are fewer studies in these
areas for valid reasons—e.g., because of an under-
lying shortage of data on the effectiveness of inter-
ventions or because cost-effectiveness is not relevant
to decisions in these areas—but the unevenness in
research productivity is cause, at least, for proactive
federal scrutiny of research in these areas. Finally,
we could not identify a funder that emphasized stud-
ies that cut across traditional disease areas.
In assessing the health economics research exam-
ining different types of interventions, previous stud-
ies have found a strong emphasis on studies of
pharmaceuticals and surgical interventions and sig-
niﬁcantly less on health education and care delivery
[2,9]. The latter areas may be “softer” and more
difﬁcult to evaluate in both clinical and health eco-
nomics studies, but they are highly relevant to
needed change in the current health and health-care
environment. Further, given the intense public focus
on costs and quality of health care, it seems logical
that the assessment of health-care delivery strategies
should be a priority for health services research,
including economic analysis.
Federally supported health economics studies do,
in fact, appear to emphasize different areas than
found in previous reviews. Publications addressing
pharmaceuticals are the most numerous interven-
tions in the articles we examined, but they represent
a noticeably lower proportion than Elixhauser et al.
[2] found in their study of CEA/CBA studies or than
Chapman et al. [9] found in their review of CUAs, a
ﬁnding consistent with the increasing role of phar-
maceutical company sponsorship of CEAs [2]. The
federally supported portfolio also included a much
lower proportion of articles considering surgical
interventions. At the same time, articles considering
health education and behavioral interventions rep-
resent a greater proportion of the federal portfolio
than in these two studies. Studies of health-care
delivery are not identiﬁed in Elixhauser et al. [2],
but they represent a greater proportion of the fed-
eral portfolio than found in the CUA database.
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It is not clear whether the differences between the
studies reviewed by Elixhauser et al. and Chapman
et al. and those we reviewed reﬂect a difference
between federal and global support of health eco-
nomics studies, or whether the focus of health eco-
nomics studies has changed over the past 5 years.
These reviews also differ in their criteria for includ-
ing health economics studies. In either case, how-
ever, it is clear that federally supported health
economics research during the past 5 years reﬂects a
lower emphasis on pharmaceuticals and surgeries
and higher emphasis on health education and
behavior and care delivery than the ﬁeld was pro-
ducing during the prior time period. As noted
earlier, however, the relatively higher numbers of
federally supported studies in health education and
behavior and in health-care delivery are driven by
studies of HIV/AIDS, substance abuse, and mental
health. In other disease areas, federally funded stud-
ies of health education and behavior and care deliv-
ery lag behind other intervention types, as do
studies supported by other funding sources.
Another concern we sought to address in exam-
ining the distribution of health economics research
across federal entities was the possibility of dupli-
cation of effort. Our review suggests that there are
signiﬁcant areas of overlap across federal funders.
Overall, the primary funders of health economics
research play different roles: each agency or insti-
tute has successfully focused the bulk of its atten-
tion on areas of study consistent with its mission.
For the NIH institutes, the focus is on speciﬁc dis-
ease areas: cancer, mental health, and substance
abuse, while at the CDC, interest has centered on
infectious disease and injuries. The VA emphasizes
substance abuse and cardiovascular disease, but
also has a signiﬁcant focus in the area of health eco-
nomics methods, as does AHRQ. The agencies also
emphasize health economics research in different
intervention types, for example, the NIMH and
NIDA’s emphasis on health education and the NCI’s
focus on screening.
Nevertheless, despite the different orientation of
the federal funders, there are many cases in which
funders are supporting the same general areas of
health economics research. For each of the ﬁve
major disease foci of health economics research we
examined, there were two to four agencies that had
supported at least 10 health economics studies over
the 5-year period. This overlap does not necessarily
constitute a duplication of effort. In some cases,
agencies collaborate actively, jointly funding studies
of interest to both, or by default, with investigators
identifying similar or complementary interests
across agencies. More often, the speciﬁc research
questions differ, although publications are in the
same area. For example, within the context of car-
diac antiarrhythmic drugs, the NHLBI is cited in a
publication examining a single drug versus a device
[21], while AHRQ is cited in a study comparing
multiple antiarrhythmic drugs and focusing on
mechanisms to evaluate drug efﬁcacy [22]. Simi-
larly, ﬁve DHHS agencies were cited as supporters
of three different studies of vertical transmission of
HIV, each assessing a different drug or surgical
option for preventing neonatal infection [23–25].
Because we were unable to identify any consistent
pattern to the agencies’ funding within the disease
areas, however, we conclude that the lack of dupli-
cation is more likely due to the numerous opportu-
nities in health economics research and/or the
initiative of individual project ofﬁcers rather than
the result of systematic planning or division of labor
among the agencies.
The overlap in health economics research, the
lack of agency-speciﬁc research foci within these
overlapping content areas, and the gaps in speciﬁc
disease and intervention areas suggest that the coor-
dination of health economics funding could be
improved. Particular efforts are warranted in areas
such as HIV/AIDS and infectious disease, which cut
across agency missions. The VA and AHRQ, which
have portfolios more diversiﬁed across disease
areas, should be particularly cognizant of research
supported by agencies with disease-speciﬁc orienta-
tions; however, most of the federal agencies support
some studies that potentially overlap with other
agencies’ work. In fact, AHRQ and the smaller
funders of health economics research—those cited
most often in publications that list more than one
source of support—may more actively coordinate
their funding efforts. Our analysis cannot verify
whether these agencies’ composite funding reﬂects
investigators’ initiative in seeking funding, agencies’
efforts to leverage their funds in areas where the
interests of different agencies overlap, or both.
Study Limitations
Our conclusions regarding the activities of federal
funders are limited by the extent and type of data
we obtained. We relied on published literature iden-
tiﬁed using PubMed, supplemented by agency con-
tacts and Web site information, as a measure of
federal funding efforts. Clearly, health economics
information can also be communicated through
unpublished reports, symposia, and other vehicles.
Although our study captures an important indicator
of funders’ efforts, it does not capture the full range
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of health economics research output. In addition,
because our study does not capture research sup-
ported by nonfederal funders, we cannot directly
compare the efforts of federal and nonfederal sup-
porters of health economics research.
The data we collected from publications are a
subset of information describing federally funded
health economics research. We did not assess the
quality of studies, an important consideration in
determining the value of funded research. In addi-
tion, unlike NIH studies to inform allocation of
NIH research dollars [5,7], we did not collect infor-
mation on the cost of studies. This information
proved difﬁcult to determine, because many health
economics studies are funded within larger clinical
studies not specifying the amounts allocated to the
various parts of the research.
The counts of published studies we present are
not always a good representation of interest in a
given area or funding priorities for other reasons.
Agencies may fund studies that are not completed
or do not result in publications; however, such fund-
ing is arguably unsuccessful, as it does not lead to
results that are widely communicated and available
for implementation in the health-care ﬁeld. A
funder may be cited for a variety of reasons, includ-
ing providing general support (e.g., a professional
development grant or a background study), as well
as for funding a speciﬁc project. There may be more
publications in some areas simply because a few
researchers are particularly productive. As a case in
point, one of three individuals is the ﬁrst author of
22 of the 64 federally supported HIV/AIDS studies
we reviewed. Although the dissemination of res-
earch results is desirable, few would argue that
success in publishing is the sole or the primary indi-
cator of the value of an author’s work. Other fac-
tors, such as the receptiveness of different journals
to publishing health economics, may also inﬂuence
the numbers of publications. The addition of new
journals may also have increased rates of publica-
tion for health economics studies over time. Clearly,
counts of publications do not always reﬂect how
well a disease area has been researched (including
the perspectives of different researchers), the effec-
tiveness of dissemination of the results, or, given the
lag between research and publishing, the most cur-
rent efforts of researchers and funders.
An important limitation of this study concerns
determining the priority of studies, particularly
among and within disease areas. As mentioned ear-
lier, a number of factors determine the importance
and relevance of a study; in our review, we are lim-
ited to broad indicators of the priority of studies
based on measures of disease health and economic
impact. A much more detailed review would be
required to determine, for example, whether an
analysis of a screening program is the ﬁrst study in
its area or whether it duplicates research on the same
topic—and if it is duplication, whether it contributes
a useful addition to the weight of evidence or adds
little value. Similarly, additional investigation would
be required to determine whether health economics
studies on a topic are lacking for an appropriate rea-
son—e.g., a lack of underlying effectiveness data or
lack of a viable alternative intervention—or whether
current areas of emphasis are less justiﬁable.
The complexity of establishing priorities for
health economics research points to a need for more
systematic methods for identifying these priorities.
Currently, federal government support of health
economics research is dictated, indirectly, by the pri-
orities of the NIH institutes, by investigators’ inter-
ests, by the composition, knowledge, and interests
of study sections, and occasionally by a directed call
for proposals for, or including, health economics. A
more systematic mechanism for identifying priori-
ties could consider the availability of clinical evi-
dence, economic burden, health impact, existence
and quality of previous health economics studies,
implementation of current interventions, and other
factors. A number of models have been developed
as a basis for this type of priority-setting effort [26].
It could highlight speciﬁc and carefully articulated
cost-effectiveness questions of interest, and identify
gaps in the evidence base and other data needed as
inputs to policy-relevant studies of cost-effective-
ness.
An effort of this type could be carried out by an
independent advisory group such as the Institute of
Medicine, which has undertaken similar projects
[6]. Alternatively, the federal agencies could con-
vene an expert panel to provide input on priorities
or, at a minimum, an interagency working group to
improve coordination of research efforts. However,
given the intense controversy surrounding the spec-
iﬁcation of cost-effectiveness questions, which may
be important in determining the ultimate cost-
effectiveness “verdict” regarding the value of an
intervention, a process with maximal independence,
transparency, and opportunity for input will likely
be the most successful.
In conclusion, our review of federally supported
health economics research suggests that, based on
available indicators, current funding strategies have
resulted in good coverage of some areas of health
economics research and less adequate coverage in
others. Coverage of disease areas appears to reﬂect
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the same trends as the global literature, focusing on
certain high-impact diseases while affording others
much less attention; in covering health-care delivery
and health education within certain disease areas,
the federally supported literature handles some
areas not well served by other funders. More speciﬁc
guidance to federal agencies regarding priorities for
health economics research would be useful but will
depend on close examination of the health econom-
ics research in speciﬁc areas or on broader priority-
setting efforts. The ultimate success of these efforts
will also depend on a balance between receptiveness
to independent investigators’ initiatives in proposing
research and a planned approach to developing
information on health economics in health care.
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Appendix A: Federal Agencies, Centers, and 
Institutes Cited for Support of At Least One 
Cost-Effectiveness or Related Study, 1997–
2001
Department of  Health and Human Services (DHHS)
Agency for Healthcare Research and Quality
(AHRQ)
Assistant Secretary for Planning and Evaluation
(ASPE)
Centers for Disease Control and Prevention (CDC)
Centers for Medicare and Medicaid Services (CMS)
Food and Drug Administration (FDA)
Health Resources and Services Administration
(HRSA)
Substance Abuse and Mental Health Services
Administration (SAMHSA)
National Institutes of Health (NIH)
Ofﬁce of the Director (OD)
National Cancer Institute (NCI)
National Eye Institute (NEI)
National Heart, Lung, and Blood Institute
(NHLBI)
National Human Genome Research Institute
(NHGRI)
National Institute of Allergy and Infectious Dis-
eases (NIAID)
National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK)
National Institute of Arthritis and Musculoskel-
etal and Skin Diseases (NIAMS)
National Institute of Child Health and Human
Development (NICHD)
National Institute of Deafness and Other Com-
munication Disorders (NIDCD)
National Institute of Dental and Craniofacial
Research (NIDCR)
National Institute of Neurological Disorders and
Stroke (NINDS)
National Institute of Environmental Health Sci-
ences (NIEHS)
National Institute of General Medical Sciences
(NIGMS)
National Institute of Mental Health (NIMH)
National Institute of Nursing Research (NINR)
National Institute on Aging (NIA)
National Institute on Alcohol Abuse and Alco-
holism (NIAAA)
National Institute on Drug Abuse (NIDA)
National Library of Medicine (NLM)
John E. Fogarty International Center (FIC)
National Center for Research Resources (NCRR)
Warren Grant Magnuson Clinical Center (CC)
Other Federal Organizations
Bureau of Labor Statistics (BLS)
Department of Defense (DOD)
Department of Education
Department of Energy (DOE)
Department of Justice
Department of Veterans Affairs (VA)
Environmental Protection Agency (EPA)
National Aeronautics and Space Administration
(NASA)
National Highway Trafﬁc Safety Administration
(NHTSA)
National Science Foundation (NSF)
United States Agency for International Develop-
ment (USAID)
United States Information Agency
United States Army
United States Navy
